AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024

CAR-T Digest - August 2020

Monthly Digest - August 2024

31 July 2024: AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024

AC Immune introduced morADC, a novel class of therapeutic antibody drug conjugates (ADCs), at AAIC 2024 for treating neurodegenerative diseases
morADC combines Morphomer® small molecules with SupraAntigen® monoclonal antibodies, enhancing brain penetration and potency to target toxic proteins in the central nervous system
Single-target morADC demonstrated significant anti-aggregation effects compared to individual antibody or small molecule treatments
Dual-targeting morADC, such as those combining anti-Abeta and anti-Tau components, showed enhanced anti-aggregation effects
The morADC technology leverages AC Immune’s SupraAntigen and Morphomer platforms, offering increased efficacy and potential advantages over existing treatments for neurodegenerative diseases